[go: up one dir, main page]

PE20151947A1 - Reduccion de la respuesta proinflamatoria - Google Patents

Reduccion de la respuesta proinflamatoria

Info

Publication number
PE20151947A1
PE20151947A1 PE2015001982A PE2015001982A PE20151947A1 PE 20151947 A1 PE20151947 A1 PE 20151947A1 PE 2015001982 A PE2015001982 A PE 2015001982A PE 2015001982 A PE2015001982 A PE 2015001982A PE 20151947 A1 PE20151947 A1 PE 20151947A1
Authority
PE
Peru
Prior art keywords
pro
inflammatory response
reduction
composition
inflammatory
Prior art date
Application number
PE2015001982A
Other languages
English (en)
Inventor
Gabriele Gross
Dirk Hondmann
Tol Erick A F Van
Marieke H Schoemaker
Teartse Tim Lambers
Original Assignee
Mjn Us Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mjn Us Holdings Llc filed Critical Mjn Us Holdings Llc
Publication of PE20151947A1 publication Critical patent/PE20151947A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La presente divulgacion proporciona un procedimiento para suprimir una respuesta proinflamatoria mediante la administracion de una composicion que comprende peptidos seleccionados a partir de un hidrolizado de caseina. Dicha composicion puede reducir los niveles de citoquinas proinflamatorias y puede ser un tratamiento para enfermedades inflamatorias, especialmente la diabetes tipo 1. Preferiblemente, el hidrolizado consiste en peptidos con un peso molecular mayor a 500 Da
PE2015001982A 2013-03-15 2014-03-11 Reduccion de la respuesta proinflamatoria PE20151947A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/838,539 US9352020B2 (en) 2013-03-15 2013-03-15 Reducing proinflammatory response

Publications (1)

Publication Number Publication Date
PE20151947A1 true PE20151947A1 (es) 2016-01-20

Family

ID=50391507

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015001982A PE20151947A1 (es) 2013-03-15 2014-03-11 Reduccion de la respuesta proinflamatoria

Country Status (16)

Country Link
US (1) US9352020B2 (es)
EP (1) EP2968437B1 (es)
CN (1) CN105142658B (es)
AR (1) AR095336A1 (es)
AU (1) AU2014237027C1 (es)
BR (1) BR112015018259A2 (es)
CA (1) CA2905820A1 (es)
ES (1) ES2821750T3 (es)
MX (1) MX2015011938A (es)
MY (1) MY177369A (es)
PE (1) PE20151947A1 (es)
PH (1) PH12015502102B1 (es)
RU (1) RU2015139359A (es)
SG (1) SG11201505693WA (es)
TW (1) TW201505647A (es)
WO (1) WO2014150571A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107708718B (zh) * 2015-04-22 2022-01-11 西达-赛奈医疗中心 用于治疗2型糖尿病的肠内递送的苦味寡肽
US20170020950A1 (en) * 2015-07-23 2017-01-26 Mead Johnson Nutrition Company Methods for modulating kinases
CA3004722A1 (en) * 2015-11-09 2017-05-18 Mjn U.S. Holdings Llc Nutritional compositions comprising lactobacillus rhamnosus gg, as well as dietary butyrate and/or a compound for stimulating formation of endogenous butyrate
US10034937B2 (en) 2015-12-04 2018-07-31 Mead Johnson Nutrition Company Synergistic nutritional compositions and uses thereof
RU2659240C2 (ru) * 2016-05-23 2018-06-29 федеральное государственное бюджетное образовательное учреждение высшего образования "Кемеровский государственный университет" (КемГУ) Способ получения функционального продукта питания для реабилитации онкологических больных
US20180160714A1 (en) * 2016-12-12 2018-06-14 Mead Johnson Nutrition Company Nutritional compositions containing butyrate and uses thereof
EP3612570A4 (en) 2017-04-17 2021-01-13 The University of Chicago POLYMERIC MATERIALS FOR THE ADMINISTRATION OF SHORT-CHAIN FATTY ACIDS TO THE INTESTINE FOR HUMAN HEALTH AND DISEASE TREATMENT APPLICATIONS
US20190208807A1 (en) * 2018-01-05 2019-07-11 Mead Johnson Nutrition Company Nutritional compositions containing milk-derived peptides and uses thereof
CN108967557A (zh) * 2018-09-29 2018-12-11 贝因美（杭州）食品研究院有限公司 一种婴儿配方食品及其制备方法
CN110204595A (zh) * 2019-06-04 2019-09-06 海普诺凯营养品有限公司 一种具有调节b淋巴细胞活性的羊乳酪蛋白水解肽及其制备方法
GB2608587B (en) * 2021-06-25 2025-01-01 Mjn Us Holdings Llc Use of extensively hydrolysed protein
CN114989247B (zh) * 2022-04-27 2024-04-02 中南林业科技大学 一种牦牛奶渣抗缺氧或低氧、抗疲劳肽及其制备方法和应用
CN117384270B (zh) * 2023-10-13 2024-07-16 华南理工大学 一种酪蛋白源dpp-iv抑制六肽及其制备方法与应用
WO2026003044A1 (en) * 2024-06-25 2026-01-02 Ntd Labs, S.L. Casein hydrolysate for treating crohn's disease

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2064092C2 (de) 1970-12-28 1983-06-01 Bayer Ag, 5090 Leverkusen Inhibitoren für Glykosidhydrolasen aus Actinomyceten
US3937817A (en) 1973-02-28 1976-02-10 Bayer Aktiengesellschaft Pharmaceutical compositions containing a saccharase inhibitor
GB1475624A (en) 1974-07-22 1977-06-01 Toyama Chemical Co Ltd Polypeptide
FR2474828B1 (fr) 1980-02-01 1983-09-09 Agronomique Inst Nat Rech Procede de traitement d'une matiere premiere a base de caseine, contenant des phosphocaseinates de cations bivalents, produits obtenus et application
FR2474829B1 (fr) 1980-02-01 1983-09-09 Agronomique Inst Nat Rech Procede de traitement d'une matiere a base de caseine contenant des phosphocaseinates de cations monovalents ou leurs derives, produits obtenus et applications
US4491589A (en) 1982-05-17 1985-01-01 The Trustees Of Columbia University In The City Of New York Amino acid solutions for parenteral nutrition and methods of formulation and use
DK589785A (da) 1985-12-18 1987-06-19 Samuelsson Ernst Gunnar Peptidpraeparat, fremgangsmaade til fremstilling deraf samt anvendelse af peptidpraeparatet
IT1190349B (it) 1986-06-16 1988-02-16 Prodotti Formenti Srl Composizioni farmaceutiche ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo,e procedimento per prepararle
FR2608050B1 (fr) 1986-12-15 1990-04-13 Bellon Labor Sa Roger Procede de preparation d'un melange peptidique riche en di- et tri-peptides, utilisable notamment en nutrition artificielle et en dietetique, melange ainsi obtenu, et utilisation de ce melange en nutrition artificielle et en dietetique
US5230902A (en) 1988-04-29 1993-07-27 Immunotec Research Corporation Undenatured whey protein concentrate to improve active systemic humoral immune response
US5102871A (en) 1989-04-24 1992-04-07 Kyowa Hakko Kogyo Co., Ltd. Nutrient composition
FI904074A7 (fi) 1989-08-28 1991-03-01 Milupa Ag Optimoidun aminohappokoostumuksen omaavat proteiini-, peptidi- ja aminohapposeokset sekä niiden käyttö keskosten ja rintalasten ravinnon sekä äidinmaidon lisäaineiden valmistamiseksi
US5407957A (en) 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
PH30997A (en) 1990-03-12 1997-12-23 Ciba Geigy Antipathologenically effective compositions comprising lytic peptides and hydrolytic enzymes.
EP1961312A3 (en) 1991-01-24 2010-03-31 Martek Biosciences Corporation Microbial oil mixture and uses thereof
US5308832A (en) 1992-07-27 1994-05-03 Abbott Laboratories Nutritional product for persons having a neurological injury
GB9310472D0 (en) 1993-05-20 1993-07-07 Univ Warwick Phenylalanine-free protein and dna coding thereof
GB9312369D0 (en) 1993-06-16 1993-07-28 Sandoz Nutrition Ltd Organic compounds
US5405637A (en) 1993-06-30 1995-04-11 Bristol-Myers Squibb Company Milk protein partial hydrolysate and infant formula containing same
US5714472A (en) 1993-12-23 1998-02-03 Nestec Ltd. Enternal formulation designed for optimized nutrient absorption and wound healing
US5723446A (en) 1993-12-23 1998-03-03 Nestec Ltd. Enteral formulation designed for optimized nutrient absorption and wound healing
US5605893A (en) 1994-03-15 1997-02-25 Children's Hospital Of Los Angeles Method of using a therapeutic food composition to diminish blood sugar fluctuations in diabetic patients
US6451368B1 (en) 1994-04-11 2002-09-17 New Zealand Dairy Board Method of selecting non-diabetogenic milk or milk products and milk or milk products so selected
US5643880A (en) 1994-05-26 1997-07-01 Abbott Laboratories Product for inhibition of attachment of H. influenzae to human cells
US5821217A (en) 1995-10-27 1998-10-13 Beth Israel Deaconess Medical Center, Inc. Enteral formulation: low in fat and containing protein hydrolysates
IT1277964B1 (it) 1995-12-27 1997-11-12 Biosistema Di Pier Luigi Spara Prodotto derivato da latte, sostanzialmente esente da betacaseina di mammifero non umano e relativo uso
KR100194074B1 (ko) 1996-02-21 1999-06-15 박종헌 글루텐 펩타이드를 유효성분으로 포함하는 미네랄 흡수 촉진제
IL127684A0 (en) 1996-07-17 1999-10-28 Nicada Inc Composition for appetite suppression
KR100221124B1 (ko) 1996-09-23 1999-10-01 한상기 신규한 카제인 및 그 제조방법
NL1005037C2 (nl) 1997-01-17 1998-07-20 Nl Zuivelonderzoek Inst Werkwijze voor het selectief afbreken van melkeiwit, in het bijzonder voor het selectief hydrolyseren van caseïne/caseïnaat in aanwezigheid van andere melkeiwitten, in het bijzonder wei-eiwitten.
CA2340223A1 (en) 1998-08-12 2000-02-24 Morinaga Milk Industry Co., Ltd. Nutritional compositions for preventing or treating hyperlipoproteinemia
US6077558A (en) 1998-12-23 2000-06-20 Bristol-Myers Squibb Company Elemental nutritional products
US6905702B1 (en) 1999-11-08 2005-06-14 Children's Hospital Los Angeles Methods for regulating blood glucose and appetite suppression in type 2 diabetics
GB9927603D0 (en) 1999-11-22 2000-01-19 Nestle Sa Use of a milk protein hydrolysate in the treatment of diabetes
EP1112693B1 (en) 1999-12-30 2006-03-22 Kerry Group Services Ltd Composition comprising carbohydrate and peptide material and its use as an energy supplement after or during physical exercise or as a metabolic nutrient for oral consumption
NL1014380C2 (nl) 2000-02-14 2001-08-15 Friesland Brands Bv Darmwandversterkend voedingsmiddel.
US6207638B1 (en) 2000-02-23 2001-03-27 Pacifichealth Laboratories, Inc. Nutritional intervention composition for enhancing and extending satiety
IL134830A0 (en) 2000-03-01 2001-05-20 Chay 13 Medical Res Group N V Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them
US7666996B2 (en) 2000-03-01 2010-02-23 Peptera Pharmaceuticals Ltd Casein derived peptides and uses thereof
TWI268138B (en) 2000-05-11 2006-12-11 Kanebo Seiyaku Ltd Composition containing peptide and electrolyte excretion enhancing substance, and food containing the same
EP1298204B1 (en) 2000-06-28 2007-04-04 Fuji Nihon Seito Corporation Novel inulin synthase and process for producing inulin by using the same
GB0016189D0 (en) 2000-06-30 2000-08-23 Pepsyn Ltd Cosmetic composition
AU9037401A (en) 2000-09-08 2002-03-22 New Zealand Dairy Board Milk containing beta-casein with proline at position 67 does not aggravate neurological disorders
WO2002032231A1 (en) 2000-10-19 2002-04-25 Edens, Luppo Protein hydrolysates
WO2003005836A2 (en) 2001-07-10 2003-01-23 Trustees Of Boston University Modified-fat nutritional products useful for preventing or treating obesity
RU2292155C2 (ru) 2001-07-18 2007-01-27 ДСМ Ай Пи ЭССЕТС Б.В. Способ гидролиза молочных белков
DE10149668A1 (de) 2001-10-09 2003-04-10 Numico Res B V Insulinmimetische Aminosäuresequenzen
JP2003137804A (ja) 2001-10-31 2003-05-14 Morinaga Milk Ind Co Ltd インターロイキン−１８誘導剤
DK1457498T3 (da) 2001-11-21 2007-06-04 Morinaga Milk Industry Co Ltd Hidtil ukendt peptid med angiotensinkonvertaseinhibitorisk virkning
EP1359157A1 (en) 2002-04-29 2003-11-05 Société des Produits Nestlé S.A. Metallo-proteinase inhibitory agent
US7460960B2 (en) 2002-05-10 2008-12-02 Epitome Biosystems, Inc. Proteome epitope tags and methods of use thereof in protein modification analysis
EP1509609B1 (en) 2002-06-04 2015-04-22 DSM IP Assets B.V. Protein hydrolysate rich in tripeptides
FR2841473B1 (fr) 2002-06-27 2004-09-17 Ingredia Utilisation d'au moins un peptide de la caseine s2 a activite inhbitrice de l'enzyme de conversion de l'engiotensine i pour la preparation de medicaments, d'aliments et de complements alimentaires
US7648957B2 (en) 2002-09-04 2010-01-19 Dsm Ip Assets B.V. Nutritional and therapeutic composition of an insulin sensitizer and a peptide fraction
TWI317636B (en) 2002-11-22 2009-12-01 Meiji Dairies Corp Nutritional compositions for liver disease patients or for patients underhigh levels of invasive stress
EP1568377A1 (en) 2002-11-29 2005-08-31 Morinaga Milk Industry Co., Ltd. Cysteine protease inhibitor
ATE490323T1 (de) 2002-12-29 2010-12-15 Toudai Tlo Ltd Adiponektin-rezeptor und dafür kodierendes gen
US7785824B2 (en) 2003-05-05 2010-08-31 Conopco Inc. Hydrolysed casein product comprising tripeptides IPP and/or VPP
EP1663298B1 (en) 2003-09-23 2019-07-17 DSM IP Assets B.V. Use of proline specific endoproteases to hydrolyse peptides and proteins
AU2004283628B2 (en) 2003-10-24 2010-07-22 N.V. Nutricia Immunemodulating oligosaccharides
BE1015863A6 (nl) 2004-01-19 2005-10-04 Huybrechts Lucas Anticariogene proteinen & peptiden & sacchariden.
EP1718158B1 (en) 2004-01-28 2014-07-02 Andromeda Bio Tech Ltd. Hsp therapy in conjunction with a low antigenicity diet
EP1568707A1 (en) 2004-02-26 2005-08-31 Puleva Biotech, S.A. Antihypertensive peptides from casein hydrolysates
KR20070007128A (ko) 2004-03-01 2007-01-12 펩테라 파마슈티컬스 엘티디. 카제인 파생 펩타이드들과 그의 치료적 사용들
KR20070034528A (ko) 2004-05-27 2007-03-28 캄피나 네덜란드 홀딩 베.붸. Ｄｐｐ－ｉｖ 매개 질병의 예방 및／또는 치료용 의약품제조를 위한 단백질 가수분해물의 용도
US8252769B2 (en) * 2004-06-22 2012-08-28 N. V. Nutricia Intestinal barrier integrity
DE102004040452A1 (de) 2004-08-20 2006-02-23 N.V. Nutricia Peptidgemisch
KR100560127B1 (ko) 2004-09-04 2006-03-13 한국기초과학지원연구원 인산화 단백질 분석용 겔-내 표지화 및 겔-내 단리 방법및 이를 이용한 단백질의 인산화 위치 동정 방법
US20080108548A1 (en) 2004-11-12 2008-05-08 N.V. Nutricia Food Composition For Rapidly Attenuating Inflammatory Responses
ATE542896T1 (de) 2004-12-23 2012-02-15 Campina Nederland Holding Bv Mit dpp-iv hemmenden peptiden angereichertes proteinhydrolysat und deren verwendung
DE602006018856D1 (de) 2005-01-18 2011-01-27 Dsm Ip Assets Bv Neue nutrazeutika-zusammensetzungen
DE602006011275D1 (de) 2005-02-03 2010-02-04 Dsm Ip Assets Bv Zusammensetzungen mit epigallocatechingallat und proteinhydrolysat
AU2006212485B2 (en) 2005-02-09 2010-03-11 Unilever Plc Food products comprising hydrolysed milk solids with improved taste
ATE497704T1 (de) 2005-04-28 2011-02-15 Unilever Nv Gesundheitsfördernde peptide und sie enthaltende zusammensetzungen
US20090131331A1 (en) 2005-04-28 2009-05-21 Dsm Ip Assets B.V. Novel Nutraceutical Compositions
EP1874327A1 (en) 2005-04-29 2008-01-09 Campina Nederland Holding B.V. Antiviral peptides
ES2319475B1 (es) 2005-06-08 2010-02-16 Consejo Superior Investig. Cientificas Peptidos bioactivos identificados en hidrolizados enzimaticos de caseinas lacteas y procedimiento de obtencion.
CA2610213C (en) 2005-07-01 2015-11-03 N.V. Nutricia Infant nutrition with hydrolised proteins
GB0523806D0 (en) 2005-11-23 2006-01-04 Micromass Ltd Mass spectrometer
WO2007064208A1 (en) 2005-11-30 2007-06-07 Campina Nederland Holding B.V. Use of a protein hydrolysate for enhancing activity of glucagon-like peptide-1
WO2008054192A1 (en) 2006-11-02 2008-05-08 N.V. Nutricia Use of nutritional compositions for preventing disorders
ATE509624T1 (de) 2005-12-23 2011-06-15 Nutricia Nv Zusammensetzung enthaltend mehrfach ungesättigte fettsäuren, proteine, mangan und/oder molybden und nukleotide/nukleoside, zur behandlung von demenz
WO2007091678A1 (ja) 2006-02-09 2007-08-16 Calpis Co., Ltd. 経口摂取用関節リウマチ抑制剤
EP2007792A2 (en) 2006-03-22 2008-12-31 DSMIP Assets B.V. Cholesterol lowering protein hydrolysates
EA200802128A1 (ru) 2006-04-12 2009-04-28 ДСМ АйПи АССЕТС Б.В. Новые нутрицевтические композиции
CA2649842C (en) 2006-04-21 2015-02-17 Meiji Seika Kaisha, Ltd. Composition containing peptide as active ingredient
EP2017283A4 (en) 2006-04-28 2015-12-30 Megmilk Snow Brand Co Ltd Peptides
KR20080003637A (ko) 2006-07-03 2008-01-08 한상기 다이어트효과가 우수한 기능성 유산균발효조성물
CN101795579A (zh) 2006-08-04 2010-08-04 Shs国际有限公司 无蛋白配方
US8642736B2 (en) 2006-08-09 2014-02-04 Dsm Ip Assets B. V. Casein complexes
NL1032840C2 (nl) 2006-11-09 2008-05-13 Friesland Brands Bv Probiotische hydrolysaatvoeding voor kinderen.
NL1033521C2 (nl) 2007-03-08 2008-09-09 Friesland Brands Bv Kindervoedingen met geoptimaliseerde aminozuursamenstelling.
KR101043251B1 (ko) 2007-04-12 2011-06-21 연세대학교 산학협력단 아연이 함유된 금속 산화물 자성 나노 입자를 포함하는자기 공명 영상제
US20090252729A1 (en) 2007-05-14 2009-10-08 Farrington Graham K Single-chain Fc (scFc) regions, binding polypeptides comprising same, and methods related thereto
US8652508B2 (en) 2007-05-25 2014-02-18 Children's Medical Center Corporation Dietary formulations and methods for treatment of inflammation and other disorders
WO2008153429A2 (en) 2007-06-11 2008-12-18 Uniwersytet Jagiellonski A protease from staphylococcus aureus, particularly spia or spib, peptides it recognises and their use
CA2699170A1 (en) 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
WO2009054435A1 (ja) 2007-10-24 2009-04-30 Otsuka Chemical Co., Ltd. 増強されたエフェクター機能を有するポリペプチド
CN102118976B (zh) * 2008-06-13 2014-02-26 N.V.努特里奇亚 用于经剖腹产分娩的婴儿的营养组合物
US8859210B2 (en) 2008-10-17 2014-10-14 Mead Johnson Nutrition Company Method for identifying allergenic proteins and peptides
JP5735734B2 (ja) 2009-04-16 2015-06-17 雪印メグミルク株式会社 脂質代謝改善剤
EP2253324A1 (en) 2009-04-30 2010-11-24 Consejo Superior De Investigaciones Cientificas Use of a casein-derived peptide and compositions thereof as antihypertensive
EP2295535A1 (en) 2009-09-11 2011-03-16 Mead Johnson Nutrition Company Probiotic material
PL2332428T3 (pl) 2009-12-04 2015-02-27 Mjn Us Holdings Llc Formulacja odżywcza zawierająca hydrolizat zawierający peptydy mleka krowiego i/lub pochodzące z niego peptydy do indukowania tolerancji
BR112012017978A2 (pt) 2010-01-19 2016-05-03 Abbott Lab fórmulas nutricionais contendo simbióticos
JP5715117B2 (ja) 2010-02-24 2015-05-07 森永乳業株式会社 摂食障害治療剤
MX376863B (es) * 2010-12-31 2025-03-07 Abbott Lab Metodos para disminuir la incidencia de la enterocolitis necrotizante en bebes, infantes, o niños al usar los oligosacaridos de leche humana.
EP2514435A1 (en) 2011-04-19 2012-10-24 Nestec S.A. Infant formula for use in the prevention of cardiovascular diseases

Also Published As

Publication number Publication date
EP2968437A1 (en) 2016-01-20
AU2014237027B2 (en) 2019-02-28
HK1216995A1 (zh) 2016-12-16
US9352020B2 (en) 2016-05-31
PH12015502102B1 (en) 2021-06-23
AU2014237027A1 (en) 2015-08-13
WO2014150571A1 (en) 2014-09-25
CA2905820A1 (en) 2014-09-25
TW201505647A (zh) 2015-02-16
CN105142658A (zh) 2015-12-09
AR095336A1 (es) 2015-10-07
MX2015011938A (es) 2015-12-01
NZ710033A (en) 2020-09-25
CN105142658B (zh) 2018-10-23
EP2968437B1 (en) 2020-07-29
RU2015139359A (ru) 2017-04-24
ES2821750T3 (es) 2021-04-27
SG11201505693WA (en) 2015-08-28
AU2014237027C1 (en) 2019-06-06
US20140271554A1 (en) 2014-09-18
PH12015502102A1 (en) 2016-01-11
MY177369A (en) 2020-09-14
BR112015018259A2 (pt) 2017-08-22

Similar Documents

Publication Publication Date Title
PE20151947A1 (es) Reduccion de la respuesta proinflamatoria
MX2016013635A (es) Métodos para aumentar los niveles de eritrocitos y tratar de la enfermedad de células falciformes.
CO2017000507A2 (es) Receptor quimérico de antígeno bcma
MX2015012576A (es) Composiciones a base de nanoparticulas.
ES2693321T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
ES2691070T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
CU20150119A7 (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
MX377340B (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
CL2014001994A1 (es) Polipeptido mimético de apelina sintéticos para el tratamiento e insuficiencia cardiaca; composicion farmacéutica que comprende dicho polipeptido.
MX2019010594A (es) Beta-caseina a2 y prevencion de la inflamacion del intestino.
MX2014014117A (es) Compuestos de d-aminoacidos para enfermedades del higado.
NI201300143A (es) Coagonista del receptor de glucagón/glp-1
DOP2016000109A (es) Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas.
MX383887B (es) Composiciones farmacéuticas y uso de las mismas para la prevención y el tratamiento de cardiomiopatía asociada a la ataxia de friedreich.
UY35548A (es) Péptidos terapéuticos para el tratamiento de trastornos metabólicos.
GT201200293A (es) Marcadores predictivos útiles en el tratamiento del síndrome frágil x (fxs)
MX2016008429A (es) Derivado de piranocromenil fenol, y composicion farmaceutica para tratar un sindrome metabolico o enfermedad inflamatoria.
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
UY36920A (es) Formulaciones de aminoácidos de liberación modificada administradas por vía oral
BR112015018335A2 (pt) Composições nutritivas contendo um componente peptídico com propriedades anti-inflamatórias e usos das mesmas
CO2017006898A2 (es) Formulación de relación fija de insulina glargina/lixisenatida
BR112013018286A2 (pt) derivados d azetidina úteis para o tratamento de doenças metabólicas e inflamatórias
PH12015502100A1 (en) Reducing the risk of autoimmune disease
MX2017009929A (es) Composiciones y métodos para metabolismo muscular mejorado.
CR20170470A (es) Tratamiento de pacientes con diabetes mellitus tipo 2

Legal Events

Date Code Title Description
FA Abandonment or withdrawal